Moderna's (MRNA) Q2 earnings and income far exceeded analyst expectations as demand stayed sturdy for its COVID-19 vaccine.
Moderna Q2 FY 2022 Earnings Report Recap
/GettyImages-1290558683-7100e3e4e48e4f61892b9164f053023c.jpg "Moderna Q2 FY 2022 Earnings Report Recap 1")
Moderna's (MRNA) Q2 earnings and income far exceeded analyst expectations as demand stayed sturdy for its COVID-19 vaccine.